lunes, 4 de diciembre de 2017

Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer. - PubMed - NCBI

Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer. - PubMed - NCBI

 2017 Nov 23. doi: 10.2217/fon-2017-0427. [Epub ahead of print]

Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.

KEYWORDS:

PAM-50; biomarker; early breast cancer; endocrine therapy; gene expression profiling; late relapse; oncotype DX; prediction

PMID:
 
29168649
 
DOI:
 
10.2217/fon-2017-0427

No hay comentarios:

Publicar un comentario